Case Report
Copyright ©The Author(s) 2024.
World J Clin Cases. Apr 16, 2024; 12(11): 1960-1966
Published online Apr 16, 2024. doi: 10.12998/wjcc.v12.i11.1960
Figure 1
Figure 1 Tissue-based assay and γ-aminobutyric acid-B receptor titer before and after treatment. A and B: Tissue-based assay (TBA)-negative case example; C and D: TBA-positive on admission; E and F: TBA positive after three months; G: Anti-γ-aminobutyric acid-B receptor (GABABR)-negative case example; H: Cerebrospinal fluid (CSF)-GABABR positive on admission (1:3.2); I: Serum-GABABR positive on admission (1:100); J: Serum-GABABR positive after two weeks (1:32); K: CSF-GABABR positive after three months (1:10); L: Serum-GABABR positive after three months (1:100). TBA: Tissue-based assay; CBA: Cell-based assay.
Figure 2
Figure 2 Brain magnetic resonance imaging scan on admission and after three months. A and E: T2 fluid-attenuated inversion recovery (FLAIR) image shows the high signal of the left amygdala; B and F: T2 FLAIR image shows the high signal of the right thalamus; C and G: T2 FLAIR image shows the high signal of the corpus callosum; D and H: T2 FLAIR image shows the high signal in the white matter surrounding the posterior part of the lateral ventricular body.